AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00105040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
Study NCT00105040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PB)
Description: Oral tablets and oral solution
Study NCT02896296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
Study NCT04664751 — intervention group
Intervention type: OTHER
Intervention: Nil-per-Oral
Description: NPO details
Study NCT01825694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Substance Abuse Intervention
Description: An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
Study NCT01273467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 0007 or placebo (Stage A)
Description: a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
Study NCT01273467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 0007 or placebo (Stage B)
Description: a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
Study NCT05936047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vertebral bone marrow clot
Description: vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
Study NCT03407833 — intervention group
Intervention type: OTHER
Intervention: Excised Liver Tissue Sampling
Description: Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
Study NCT00538863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
Study NCT00201396 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: Radiation with weekly Cisplatin
Study NCT00201396 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Radiation with weekly Cisplatin
Study NCT00201396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
Description: Induction C/T + CCRT
Study NCT01751919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate tablet 400 mg, 1 Tablet
Study NCT01751919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glivec film-coated tablet 100 mg, 4 Tablets
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE+beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+Somatostatin
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
Study NCT05055713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+PSE+Somatostatin
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study NCT02704832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatrician Intervention
Description: Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
Study NCT02582944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus BF-180 bronchoscope (standard adult)
Description: -Standard of care
Study NCT02582944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veran Spinview Thoracic Navigation System
Description: -Electromagnetic navigation
Study NCT02582944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus UM-S20-17S
Description: -Endobronchial ultrasound mini-probe
Study NCT02582944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study NCT03837158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early loading
Description: two TiZr implants on SLA surface
Study NCT03837158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: four TiZr implants on SLA surface
Study NCT01790308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Study NCT00387660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02401555 — intervention group
Intervention type: DEVICE
Intervention: Geenius HIV1/2 Supplemental Assay
Description: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
Study NCT02242890 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contraception Information Packet
Description: The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
Study NCT03116347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cuvitru
Description: 200 mg/ml solution for Immune Globulin Subcutaneous Injection
Study NCT02836600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study NCT03249493 — intervention group
Intervention type: OTHER
Intervention: Blood sample on DBS
Description: We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL
Study NCT05585788 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Addinex Device (ADX-27)
Description: The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians.
Study NCT02297282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Description: Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
Study NCT01395862 — intervention group
Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Study NCT01880047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
Study NCT01880047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2800 mg/m2 iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil
Description: 2800 mg/m2 iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: 400 mg/m2 iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium folinate
Description: 400 mg/m2 iv
Study NCT00941382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine-Metformin
Description: sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
Study NCT00941382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: 15 mg per day for 180 days
Study NCT04484519 — intervention group
Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg OR 7.5 mg/kg iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg OR 7.5 mg/kg iv
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2 orally daily for two weeks
Study NCT04245865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2 orally daily for two weeks
Study NCT04245865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 300 mg orally x 3 daily
Study NCT04245865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally x 3 daily
Study NCT02762890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
Study NCT02762890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
Study NCT01292265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
Study NCT04970589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mango
Description: 400g of mango/day
Study NCT04970589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 400g of mango/day
Study NCT04970589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 1 probiotics capsule/day
Study NCT04970589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo capsule/day
Study NCT04970589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 Placebo capsule/day
Study NCT03588429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
Study NCT03588429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
Study NCT01704573 — intervention group
Intervention type: DRUG
Intervention: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
Description: The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.
Study NCT05175378 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle intervention
Description: We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
Study NCT05175378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
Study NCT00693511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training
Description: Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
Study NCT00693511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit training + motivational interviewing
Description: Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
Study NCT02006836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pomelo
Description: The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
Study NCT02006836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: We dissolved 50 g of glucose in 200 ml water.
Study NCT02006836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blank
Description: For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
Study NCT02006836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
Study NCT02006836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: met or diet
Description: In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
Study NCT04343833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implants
Description: At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
Study NCT00941382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg per day for 180 days
Study NCT00417482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: risperidone
Description: Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
Study NCT03403270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENCOURAGE App
Description: Users will have an opportunity to engage with the app as described for the duration of the study period.
Study NCT02793193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
Study NCT02793193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo for antibiotic
Description: The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
Study NCT02793193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Antibiotic Xifaxan ® will be 200mg per tablet
Study NCT02793193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo for probiotic
Description: The placebo identical-looking to the probiotic B.longum 1714
Study NCT04330196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participant ingests 75g of glucose
Study NCT04330196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of placebo
Description: Participant ingests 700mg of aspartame
Study NCT01859585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib 40 mg intravenous
Study NCT01859585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 30 mg intravenous
Study NCT04054154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Undergo shear wave elastography
Study NCT04054154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Interstitial Fluid Pressure Measurement
Description: Undergo tumor pressure measurement
Study NCT02236481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Study NCT02236481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF alpha inhibitors